证券代码：300318 证券简称：博晖创新 公告编号：临 2023-046 北京博晖创新生物技术集团股份有限公司 第八届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、审议通过《2023 年半年度报告及其摘要》 经审核，监事会认为公司编制的《2023 年半年度报告》及其摘要的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。同意票数占总票数的 100%。 三、备查文件 1、第八届监事会第二次会议决议。 特此公告。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第二次会议于 2023 年 8 月 29 日在公司会议室召开，会议通知于 2023 年 8月 18日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司监事 会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议应出 席监事 3 人，实际出席监事 3 人。本次 ...

证券代码：300318 证券简称：博晖创新 公告编号：临 2023-045 同意公司根据《深圳证券交易所创业板股票上市规则》、《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》等法律、法规 的相关要求，结合本公司 2023 年上半年的实际经营管理情况编制的《2023 年半 年度报告》及其摘要，该报告及其摘要未经会计师事务所审计。 北京博晖创新生物技术集团股份有限公司 第八届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 第八届董事会第二次会议于 2023 年 8 月 29 日在公司会议室召开，会议通知于 2023 年 8 月 18 日以专人送达、邮件通知或电话通知的方式送达各位董事，会议 由公司董事长沈治卫先生主持，会议采取现场和通讯表决相结合方式进行，本次 会议应出席董事 7 人，实际出席董事 7 人，监事和高级管理人员列席了会议。本 次会议的召集召开程序符合《公司法》和《公司章程》的有关规定。 二、董事会 ...

北京博晖创新生物技术集团股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | 资金占用方名称 | 占用方与上市 | 上市公司核算的 | 2023 | 年期初占用资 | 2023 年 | 1-6 月份占用 | 2023年1-6月份占用 | | 2023年1-6月份偿 | 2023 年 | 6 月期 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 公司的关联关 | 会计科目 | | 金余额 | | 累计发生金额（不含利 | 资金的利息（如有） | | 还累计发生金额 | 末占用资金余 | | 因 | | | | | 系 | | | | | 息） | | | | 额 | | | | | 控股股东、实际控制人 | - | - | - | | - | | - | - | | - | - | | | | | 及其附属企业 | | - | - | | - | | - | - | | ...

2、公司没有为控股股东、实际控制人及其他关联方、任何非法人单位或个 人提供担保的情形；控股股东、实际控制人及其他关联方也未强制公司为他人 提供担保。截至报告期末，公司不存在任何对外担保情形。 （以下无正文） （本页无正文，为《北京博晖创新生物技术集团股份有限公司独立董事关于第八 届董事会第二次会议相关事项的独立意见》之签字页） 独立董事签名： 北京博晖创新生物技术集团股份有限公司独立董事 关于第八届董事会第二次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等法 律法规、规范性文件，以及《北京博晖创新生物技术集团股份有限公司章程》《北 京博晖创新生物技术集团股份有限公司独立董事工作规则》等有关规定，作为北 京博晖创新生物技术集团股份有限公司（以下简称"博晖创新"或"公司"）的独立 董事，我们基于实事求是、独立判断的立场和态度，在审阅相关议案资料后，基 于独立判断立场，本着认真负责的态度对公司第八届董事会第二次会议审议的以 下相关事项进行了认真审议并发表如下独立意见： 一、关于控股股东及其他关联方占用 ...

证券代码：300318 证券简称：博晖创新 | --- | |------------| | | | 投资者关系 | | 活动类别 | | | | | | 参与单位名 | | | | 称及人员姓 | | | | 名 | 时间 2023 年 7 月 13 日 10:00-11:00 地点 公司会议室 上市公司接 待人员姓名 董事、副总经理、董事会秘书 董海锋先生 1、公司目前有几个血液制品牌照，血液制品板块未来布局/计 划？ 答：公司目前有 3 个血液制品生产企业，分别是位于河北石 家庄的博晖生物制药（（河北）有限公司（（（ 河北博晖"），位于河北 投资者关系 廊坊的博晖生物制药股份有限公司（（（ 廊坊博晖"），以及位于广东 活动主要内 汕头的广东卫伦生物制药有限公司（（（ 广东卫伦"）。另外，公司已 容介绍 经在云南曲靖投资建成了 1500 吨加工能力的血制生产工厂，目前 正在进行血制生产资质迁址至云南工厂的相关工作。同时，为了 拓展血浆资源和市场区域，在内蒙古呼和浩特筹建了一个新的血 液制品生产工厂，未来待内蒙古工厂建成后，计划将旗下的一个 血制生产资质迁至内蒙古工厂。 北京博晖创新生物技术集团股份有限公司 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | |------------|---------------------------------| | | 特定对象调研 | | 投资者关系 | □媒体采访 | | 活动类别 | □新闻发布会 | | | □现场参观 | | | □其他（请文字说明其他活动内容） | | 参与单位名 | | | | 国金证券股份有限公司 | | 称及人员姓 | | | | 农银汇理基金管理有限公司 | 名 时间 2023 年 6 月 26 日 15:00-16:00 地点 公司会议室 上市公司接 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、能简单介绍一下大股东情况吗？ 答：公司大股东是杜江涛先生，持有本公司 39.03%股份。另 外，杜江涛先生也持有另一家上市公司君正集团（股票代码： 601216）31.95%股份。 投资者关系 2、公司血液制品业务主要依靠哪些资源发展？ 活动主要内 答：公司自进入血液制品业务以来，在产品研发、浆站拓展方 容介绍 面进行了持续投入，并获得了一定成效，产 ...

证券代码： 300318 证券简称：博晖创新 北京博晖创新生物技术集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------|---------------------------------|---------| | | | 2023-01 | | | □特定对象调研 | | | 投资者关系 | □媒体采访 | | | 活动类别 | □新闻发布会 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名 | | | | 称及人员姓 | 线上参与公司 2022 | | 名 时间 2023 年 5 月 10 日 15:00-17:00 地点 价值在线（https://www.ir-online.cn/）网络互动 董事长 沈治卫先生 上市公司接 独立董事 班均先生 待人员姓名 董事、财务总监兼董事会秘书 董海锋先生 1、请问沈董事长，中科生物生产设备进行升级改造进展如 何？何时能恢复正常生产？ 答：中科生物维修改造正按照计划积极推进中，目前正在按 投资者关系 照监管法规要求进行信息化改造，后续需政府相关部门进行验收， 活动 ...

Financial Performance - The company's revenue for Q1 2023 was ¥252,950,995.14, representing a 44.22% increase compared to ¥175,394,242.89 in the same period last year[5] - Net profit attributable to shareholders was ¥5,174,206.08, a significant turnaround from a loss of ¥13,243,101.60 in Q1 2022, marking a 139.07% increase[5] - Basic earnings per share rose to ¥0.0063 from a loss of ¥0.0162, indicating a 138.89% improvement[5] - Total operating revenue for Q1 2023 was CNY 252,950,995.14, an increase of 44.4% compared to CNY 175,394,242.89 in Q1 2022[28] - Net profit for Q1 2023 reached CNY 9,672,620.16, a significant recovery from a net loss of CNY 26,680,596.65 in Q1 2022[29] - The company reported a gross profit margin of approximately 4.9% for Q1 2023, compared to a negative margin in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 9,156,153.67, compared to a loss of CNY 26,934,387.20 in the same period last year[30] Cash Flow and Financial Position - The net cash flow from operating activities improved to ¥5,173,217.62, compared to a negative cash flow of ¥29,404,292.88 in the previous year, reflecting a 117.59% increase[5] - The company reported a decrease in cash and cash equivalents to ¥93,007,540.49 from ¥113,600,046.91 at the beginning of the year, representing a decline of approximately 18.3%[22] - The company’s cash and cash equivalents were CNY 1,103,368,335.50, down from CNY 1,140,130,256.34 in the previous year[24] - The net cash flow from financing activities was CNY 39,680,216.45, a decrease from CNY 132,357,092.92 in the previous year[34] - The company incurred cash outflows from investing activities totaling CNY 65,391,879.04, compared to CNY 37,529,195.84 in the same period last year[34] - The company received CNY 311,022,700.66 in cash from borrowings, significantly higher than CNY 68,000,000.00 in the previous year[34] - The total cash inflow from financing activities was CNY 693,022,700.66, compared to CNY 237,100,000.00 in the same period last year[34] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,883,039,678.80, a slight decrease of 0.64% from ¥3,908,002,277.01 at the end of the previous year[5] - Total liabilities decreased to CNY 1,550,004,592.03 in Q1 2023 from CNY 1,584,123,343.91 in Q1 2022[25] - The company’s equity attributable to shareholders increased to CNY 1,398,188,443.27 from CNY 1,393,532,991.70 year-over-year[26] Operational Highlights - The company experienced a 40.62% increase in cash received from sales, totaling ¥258,419,243.49, driven by growth in blood product sales[12] - The company reported a 715.48% increase in other income, amounting to ¥1,781,470.44, primarily due to increased government subsidies received[10] - The company’s financial expenses decreased by 50.34% to ¥6,238,699.81, attributed to a reduction in short-term debt[10] - Revenue from sales of goods and services received cash of CNY 258,419,243.49, up from CNY 183,767,004.44 in the prior year[32] Shareholder Information - Major shareholder Du Jiangtao holds 39.03% of the shares, totaling 318,811,388 shares[15] - The company has a total of 20,001,720 shares under lock-up, with 178,500 shares released during the period[18] - The company’s vice president reduced her holdings by 179,000 shares at an average price of ¥6.1128 per share, accounting for 0.0219% of the total share capital[19] Investments and Development - The company’s cash outflow for the purchase of fixed assets increased by 74.43% to ¥65,391,879.04, reflecting ongoing investments in the Yunnan blood product project[12] - The company provided guarantees totaling up to ¥650 million for its subsidiaries, with ¥250 million specifically allocated for financing through a cloud platform[20] - The company’s subsidiary obtained a single plasma collection license from the Yunnan Provincial Health Commission[20] - Research and development expenses for Q1 2023 were CNY 14,197,200.03, slightly up from CNY 13,783,836.86 in Q1 2022[29] Receivables and Inventory - Accounts receivable decreased to ¥65,251,577.57 from ¥75,921,242.82, a reduction of about 13.9%[23] - Inventory slightly decreased to ¥860,199,805.87 from ¥870,516,782.75, indicating a decrease of approximately 1.4%[23] - The company’s total receivables from financing decreased to ¥3,120,031.32 from ¥6,485,146.87, a decline of approximately 51.8%[23] - The company’s prepayments increased to ¥15,106,599.30 from ¥8,255,312.80, reflecting an increase of about 83.3%[23]

Financial Performance - The company reported a total revenue of 816.9 million RMB for the year 2022, with no cash dividends distributed to shareholders[5]. - The company's operating revenue for 2022 was ¥795,932,495.41, an increase of 11.36% compared to ¥714,748,462.45 in 2021[20]. - The net profit attributable to shareholders was -¥78,325,488.76, showing a 75.69% improvement from -¥322,176,629.03 in 2021[20]. - The cash flow from operating activities reached ¥40,718,935.07, a significant increase of 4,486.61% compared to ¥887,777.88 in 2021[20]. - The total assets at the end of 2022 amounted to ¥3,908,002,277.01, reflecting a 5.91% increase from ¥3,690,026,740.04 at the end of 2021[20]. - The net assets attributable to shareholders increased by 42.96% to ¥1,393,532,991.70 from ¥974,752,736.01 in 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.0959, improving by 75.68% from -¥0.3944 in 2021[20]. - The company's revenue after deducting non-recurring items was ¥751,603,420.53, up from ¥682,179,143.93 in 2021[21]. - The company’s non-recurring gains totaled ¥17,248,995.25 in 2022, compared to ¥14,891,931.39 in 2021[27]. - The revenue from the biological products segment was ¥503.41 million, accounting for 63.25% of total revenue, with a year-on-year growth of 31.52%[84]. - The revenue from the testing and inspection segment was ¥248.20 million, which represented a decline of 17.11% year-on-year[84]. - The company achieved a gross margin of 15.67% in the biological products segment, which decreased by 9.42% compared to the previous year[87]. - The total revenue for the company in 2022 was approximately ¥795.93 million, representing an increase of 11.36% compared to ¥714.75 million in 2021[84]. Market Position and Strategy - The company maintains a strong commitment to research and development in microfluidic chip technology and molecular diagnostics[13]. - The company is focused on expanding its product offerings based on its existing technology platform to enhance its market presence[39]. - The company is a leader in the trace element detection market, with a stable user base and established products in hospitals[39]. - The company has established a stable partnership with multiple distributors across the country, enhancing its market position through innovative technology and customer network[54]. - The company aims to enhance its market presence through the development of innovative medical devices and technologies[59]. - The company is focused on expanding its operations in the biopharmaceutical market, with plans for potential mergers and acquisitions to enhance its competitive position[180]. - The company is actively pursuing new strategic investments in the blood products sector to enhance its market position[79]. - The company aims to enhance its blood product business by increasing operational efficiency and expanding its market presence over the next 3-5 years[133]. Product Development and Innovation - The company is committed to continuous innovation in the field of medical diagnostics, with multiple products in the pipeline for the next few years[62]. - The company is developing several new diagnostic products, including a high-risk HPV test kit and a respiratory pathogen test kit, aiming for market competitiveness[97]. - The company has developed a series of diagnostic kits for measuring various elements in human blood, including copper, zinc, calcium, magnesium, and iron, with expected launch dates in July 2024[62]. - The company plans to launch a series of new diagnostic kits, including the Procalcitonin Test Kit and the 25-Hydroxyvitamin D Test Kit, with expected registration dates in March 2025[63]. - The company is expanding its product line with a new C-reactive protein testing kit, expected to launch in March 2025, to assess inflammation levels[62]. - The company is focusing on enhancing its diagnostic capabilities through the introduction of quantum dot fluorescence immunoassay methods for various tests[62]. - The Quantum Dot Fluorescence Immunoassay technology is expected to improve the accuracy and efficiency of diagnostic testing[63]. - The company has developed over 20 patents related to its microfluidic chip molecular diagnostic platform, establishing a competitive edge in the automated molecular diagnostic field[76]. Regulatory Compliance and Governance - The company emphasizes its dedication to compliance with regulatory standards set by the China Securities Regulatory Commission[11]. - The company’s blood product offerings comply with strict regulatory policies, which pose challenges for market entry[47]. - The company has passed certifications for medical device GMP, ISO13485, and ISO9001, ensuring high-quality product management[80]. - The company maintains a strict governance structure, ensuring independence from its controlling shareholder in terms of assets, personnel, finance, and operations[159]. - The company has established an independent financial accounting system and management practices, ensuring compliance with relevant laws and regulations[163]. - The company has a dedicated investor relations management system to foster good interactions with investors and maintain a positive image in the capital market[157]. Human Resources and Management - The total number of employees at the end of the reporting period was 1,773, with 299 in the parent company and 1,474 in major subsidiaries[196]. - The company employed 933 technical personnel, 343 production staff, and 197 sales personnel, indicating a strong focus on technical expertise[196]. - The educational background of employees included 24 with doctoral degrees, 50 with master's degrees, and 556 with bachelor's degrees, reflecting a highly educated workforce[196]. - The company implemented a competitive compensation policy to attract and retain talent, ensuring alignment with market standards[198]. - Employee benefits included annual health check-ups, supplemental medical insurance, and various welfare programs to enhance employee satisfaction and loyalty[198]. - The company has maintained a stable management team with no significant changes in senior management positions[171]. - The financial director, Dong Haifeng, has extensive experience in investment management and financial oversight, contributing to the company's financial health[181]. Challenges and Risks - The company is facing risks related to the slow progress of key projects, particularly the resumption of production at Zhongke Biological and the migration of production qualifications for the Yunnan blood product project, which require government approvals[144]. - Continuous investment in R&D, fixed assets, and market promotion has led to a tight financial situation, necessitating increased fundraising efforts to meet business development needs[145]. - The company has established a comprehensive quality management system to address potential risks related to product safety and regulatory compliance[141]. - The company is committed to ensuring product safety and quality control to mitigate risks associated with blood products[140]. Sales and Marketing - The company’s main business revenue from inspection and testing reached 248.2 million yuan, a year-on-year decrease of 17.11%, with medical testing products generating 140.96 million yuan, down 30.22%[55]. - The sales volume of blood products increased by 45.62% year-on-year, with significant contributions from intravenous immunoglobulin and human albumin[90]. - The company’s strategy includes expanding its market presence through competitive pricing and new sales channels, as evidenced by its procurement successes[68]. - The company achieved a sales volume of 527,958 bottles of intravenous immunoglobulin, marking a 35.51% increase from 389,602 bottles in the previous year[70]. Shareholder and Board Information - The annual shareholders meeting had a participation rate of 42.53%[166]. - The company reported a total of 26,906 shares held by directors and supervisors at the end of the reporting period[169]. - The chairman of the board, Zhai Xiaofeng, resigned on May 31, 2022, due to personal reasons[170]. - The board of directors consists of 7 members, including 3 independent directors, who actively participate in training and decision-making processes[152]. - The total remuneration for directors, supervisors, and senior management amounted to 5.5753 million yuan[188].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"博晖创新"或"公司"） 2022年年度报告及其摘要已于2023年4月26日刊登于中国证监会指定信息披露网站。 为便于投资者能够进一步了解公司的生产经营情况，公司将于2022年5月10日（星期 三）15:00 —17:00在价值在线（www.ir-online.cn）举办2022年度业绩说明会。 本次业绩说明会将采用网络远程的方式举行，投资者可登陆价值在线（www.ir- online.cn）参与本次年度业绩说明会。 参加本次年度业绩说明会的人员情况如下：董事长沈治卫先生，独立董事班均 先生，董事、财务总监兼董事会秘书董海锋先生。 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-011 北京博晖创新生物技术集团股份有限公司 关于举行 2022 年度业绩网上说明会的公告 证券代码：300318 证券简称：博晖创新 公告编号：临 2023-011 特此公告。 北京博晖创新生物技术集团股份有限公司 董 事 会 2023 年 4 月 26 日 为充分尊重投 ...